The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
Global Initiative on Digital Health launched at the G2O Health Minister’s Meeting
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
India is committed to eliminating Lymphatic Filariasis by 2027, three years ahead of the global target through mission mode, multi partner, multi sector targeted drive
Subscribe To Our Newsletter & Stay Updated
